Decrease of neurofilament is associated with reduction of clinical disease activity in glatiramer acetate treated people with multiple sclerosis

被引：0
|
作者：
Konofalska, U. [1 ]
Akgun, K. [1 ]
Proschmann, U. [1 ]
Haase, R. [2 ]
Ziemssen, T. [1 ]
机构：
[1] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Dept Neurol, Ctr Clin Neurosci, Dresden, Germany
[2] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P599
引用
收藏
页码：526 / 527
页数：2
相关论文
共 50 条
  • [21] Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis
    Weder, C
    Baltariu, GM
    Wyler, KA
    Gober, HJ
    Lienert, C
    Schluep, M
    Radü, EW
    De Libero, G
    Kappos, L
    Duda, PW
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (11) : 869 - 878
  • [22] Anti-glatiramer acetate antibody levels in treated multiple sclerosis patients
    Oger, J
    Gibb, E
    Basile, E
    Aziz, T
    MULTIPLE SCLEROSIS, 2005, 11 (01): : 119 - 119
  • [23] T Cell Renewal in Glatiramer Acetate-Treated Multiple Sclerosis Patients
    Chiarini, Marco
    Capra, Ruggero
    Sottini, Alessandra
    Serana, Federico
    Ghidini, Claudia
    Zanotti, Cinzia
    Cordioli, Cinzia
    Rottoli, Maria Rosa
    Zaftoroni, Mauro
    Imberti, Luisa
    NEUROLOGY, 2009, 72 (11) : A36 - A36
  • [24] Antibodies to glatiramer acetate in long-term treated multiple sclerosis patients
    Teitelbaum, D
    Arnon, R
    Karussis, D
    Abramsky, O
    Brenner, T
    MULTIPLE SCLEROSIS, 2005, 11 : S163 - S163
  • [25] Early Clinical Predictors of Sustained Disease-Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Interferon Beta and Glatiramer Acetate
    Martinez, A.
    Rojas, G.
    Curbelo, C.
    Vrech, C.
    Steinberg, J.
    Carra, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1835 - 1835
  • [26] Early Clinical Predictors of Sustained Disease-Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Glatiramer Acetate and Interferon Beta
    Rojas, Galeno
    Vrech, Carlos
    Leguizamon, F.
    Lindembaum, S.
    Carra, Adriana
    NEUROLOGY, 2012, 78
  • [27] T Cell Activation and Th2 Cytokine Secretion Correlate with Disease Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
    Sellebjerg, Finn
    Krakauer, Martin
    Hesse, Dan
    Lund, Henrik
    Sondergaard, Helle B.
    Sorensen, Per S.
    NEUROLOGY, 2009, 72 (11) : A471 - A472
  • [28] Gene expression profile and clinical outcome in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate
    Achiron, Anat
    Magalashvili, David
    Dolev, Mark
    Sonis, Polina
    Gurevich, Michael
    NEUROLOGY, 2007, 68 (12) : A313 - A314
  • [29] Multiple sclerosis Glatiramer acetate - have the CIS and also for young people make sense
    Oetzel, Stefan
    PSYCHOPHARMAKOTHERAPIE, 2009, 16 (03): : 138 - 139
  • [30] Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
    Foong, Yi Chao
    Merlo, Daniel
    Gresle, Melissa
    Zhu, Chao
    Buzzard, Katherine
    Zhong, Michael
    Yeh, Wei
    Jokubaitis, Vilija
    Butzkueven, Helmut
    van der Walt, Anneke
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (04) : 24 - 25
12345